City Therapeutics, Inc. has made significant strides in its clinical development efforts by announcing that the first participant has been dosed in a Phase 1 clinical trial of CITY-RBP4. This investigational RNA interference (RNAi) therapeutic candidate aims to treat Stargardt disease, a condition that currently has no approved therapies. The trial's progress is crucial for City Therapeutics as it seeks to address a major unmet medical need in the field of retinal diseases.
Founded in Cambridge, Massachusetts, City Therapeutics, Inc. operates under the Standard Industrial Classification (SIC) code 2834, which pertains to pharmaceutical preparations. The company focuses on developing innovative RNAi therapeutics aimed at delivering meaningful and durable benefits for patients. It trades on the Nasdaq under the ticker symbol CTY and is classified as an emerging growth company.
According to the recent SEC filing (accession number 0001104659-26-124775), City Therapeutics issued a press release on November 10, 2026, detailing the dosing of the first participant in the Phase 1 trial of CITY-RBP4. The company stated, “Advancing CITY-RBP4 into the clinic brings us an important step closer to addressing that unmet need, while also reflecting the significant progress of our pipeline.” This trial is designed to evaluate the safety, tolerability, and pharmacokinetics of the drug.
The Phase 1 trial is a first-in-human, multicenter, randomized, double-masked, placebo-controlled study involving healthy volunteers and individuals with Stargardt disease. Participants will receive single and multiple subcutaneous doses of CITY-RBP4, with assessments focusing on the drug's pharmacodynamics and safety. City Therapeutics plans to report initial data from the trial in mid-2027.
This development may significantly impact patients suffering from Stargardt disease, as the condition leads to irreversible vision loss and currently lacks effective treatments. The trial's success could also influence the competitive landscape within the pharmaceutical preparations industry, particularly among companies focused on innovative retinal therapies.
The filing does not specify what happens next, but the company is expected to continue monitoring the trial's progress and will likely provide updates as data becomes available.
Read Next
Q/C Technologies Enters Omnibus Amendment Agreement
ONE Nuclear Energy settles consulting fees with stock issuance
HCW Biologics delays stockholder vote amid quorum issues
bioAffinity Technologies amends share structure in 8-K filing
VisionWave amends sponsorship deal with Hen Basketball Haifa Club
Apimeds Pharmaceuticals Amends Agreement with FreeT Inc.










